Nuclidium
Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. The company's platform provides new diagnostic and therapeutic tracers in which specific target molecules will fir...
Valuation
$163.2M
Latest known
Share Price
N/A
Total Raised
$100.6M
Last Round
N/A